Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Peptide Inhibition of Drug Efflux Pumps
EF 2016-17
Résumé
Antibiotic resistance is quickly becoming a prominent global health concern. Current antibiotic drugs used to treat bacterial infections are continually decreasing in effectiveness as bacteria evolve and become resistant to treatment. One of several mechanisms through which bacteria may become resistant is by overproducing efflux pumps. Essentially these pumps are membrane-embedded proteins that can recognize a wide range of antibiotic drugs and extrude them from the bacteria's cellular environment before the drug can exert its effect. The largest family of these proteins with the capability of pumping a broad range of drugs and other toxic substances is called the resistance-nodulation-cell division (RND) superfamily. The primary goal of my project is to design a peptide-based drug to inhibit the function of this family of pumps. As the RND pumping mechanism has been shown to function through the association of three identical protein subunits situated within the bacterial membrane, I have constructed synthetic peptides designed to mimic the helix-helix interface through which the protein subunits interact. We hypothesize these peptides will bind at this locus and disrupt the functional interface, thus hindering the pumping capability. Initially, a fluorescent toxicant molecule ethidium bromide will be used to monitor the efficacy of the synthetic peptides. The structural makeup of the synthetic peptides will be optimized to ensure maximal activity while circumventing toxicity to human cells. In the absence of new classes of antibiotics, these peptide drugs represent a novel approach toward boosting the activity of our current antibiotics.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367157
Name
Jesin Joshua A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Peptide Inhibition of Drug Efflux Pumps
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acrb; Antibiotic Resistance; Cystic Fibrosis; Efflux Pumps; Membrane Proteins; Peptide Synthesis; Protein Inhibition
Abstract
Antibiotic resistance is quickly becoming a prominent global health concern. Current antibiotic drugs used to treat bacterial infections are continually decreasing in effectiveness as bacteria evolve and become resistant to treatment. One of several mechanisms through which bacteria may become resistant is by overproducing efflux pumps. Essentially these pumps are membrane-embedded proteins that can recognize a wide range of antibiotic drugs and extrude them from the bacteria's cellular environment before the drug can exert its effect. The largest family of these proteins with the capability of pumping a broad range of drugs and other toxic substances is called the resistance-nodulation-cell division (RND) superfamily. The primary goal of my project is to design a peptide-based drug to inhibit the function of this family of pumps. As the RND pumping mechanism has been shown to function through the association of three identical protein subunits situated within the bacterial membrane, I have constructed synthetic peptides designed to mimic the helix-helix interface through which the protein subunits interact. We hypothesize these peptides will bind at this locus and disrupt the functional interface, thus hindering the pumping capability. Initially, a fluorescent toxicant molecule ethidium bromide will be used to monitor the efficacy of the synthetic peptides. The structural makeup of the synthetic peptides will be optimized to ensure maximal activity while circumventing toxicity to human cells. In the absence of new classes of antibiotics, these peptide drugs represent a novel approach toward boosting the activity of our current antibiotics.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jesin, Joshua A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~